Company Description

CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally.

The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular system to the autonomic nervous system.

It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

CVRx, Inc.

Country	United States
Founded	2000
IPO Date	Jun 30, 2021
Industry	Medical Devices
Sector	Healthcare
Employees	223
CEO	Kevin Hykes

Contact Details

Address: 9201 West Broadway Avenue, Suite 650 Minneapolis, Minnesota 55445 United States
Phone	763 416 2840
Website	barostim.com

Stock Details

Ticker Symbol	CVRX
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$18.00
CIK Code	1235912
CUSIP Number	126638105
ISIN Number	US1266381052
SIC Code	3841

Key Executives

Name	Position
Kevin Hykes	President, Chief Executive Officer and Director
Dr. Philip B. Adamson M.D., M.Sc.	Chief Medical Officer

Latest SEC Filings

Date	Type	Title
Aug 24, 2026	SCHEDULE 13D	Filing
Aug 14, 2026	SCHEDULE 13G	Filing
Aug 11, 2026	8-K	Current Report
Aug 6, 2026	10-Q	Quarterly Report
Aug 6, 2026	8-K	Current Report
Jun 9, 2026	8-K	Current Report
Jun 3, 2026	8-K	Current Report
May 28, 2026	SD	Form - SD
May 12, 2026	10-Q	Quarterly Report
May 11, 2026	8-K	Current Report

View All SEC Filings